Sanofi posts strong Q3 results, lifts FY‑2026 sales and EPS outlook

Sanofi reported third‑quarter 2026 adjusted earnings of $2.04 per share, beating the $1.63 consensus by 25.15%. Net sales reached $16.623 billion, or €14.444 billion at constant exchange rates, up 14.3% year‑on‑year. Dupixent drove growth with €5.7 billion in sales, a 34.8% increase, while business EPS rose to €3.55, up 22% on a reported basis. The company upgraded its full‑year guidance, now expecting low‑teens percentage sales growth and mid‑teens percentage business EPS growth for FY‑2026.

The guidance upgrade signals higher future revenue and earnings, which could support the stock price (the company expects low‑teens sales growth and mid‑teens EPS growth, per the FY‑2026 outlook). Analysts note the strong Dupixent performance and the plan to pursue larger M&A deals to sustain growth ().

  • 1Adjusted EPS for Q3 FY26 was $2.04, beating the $1.63 consensus by 25.15%.
  • 2Quarterly sales were $16.623 billion, exceeding the $15.230 billion estimate by 9.15%.
  • 3Net sales at constant exchange rates were €14.444 billion, up 14.3% year‑on‑year.
  • 4Dupixent sales were €5.7 billion, up 34.8% year‑on‑year.
  • 5Business EPS was €3.55, up 22% on a reported basis.
  • 6FY‑2026 sales growth outlook was raised to a low‑teens percentage at constant exchange rates.

Sources